Back

Prognostic value of asymptomatic coronary artery disease and coronary artery calcium score for the risk of cancer therapy-related cardiac dysfunction (ANTEC study)

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: around the world Cardio-Oncology ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Anna Borowiec

National Institute of Oncology, Warsaw, Poland, Warsaw (Poland)

5 More presentations in this session

Presentation thumbnail
Cardiovascular outcomes of sodium glucose co-transporter-2 inhibitor treatment in cancer patients receiving anthracycline chemotherapy: a systematic review and meta-analysis
Doctor R. Cordovez (Cebu City, PH)
Abstract Slides Video
Presentation thumbnail
Temporal trends and outcomes of amyloidosis in Korea: a 13-year nationwide cohort study with a focus on cardiac involvement
Doctor M. Jung (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Echocardiographic assessment of early radiotherapy-induced cardiotoxicity in breast cancer patients
Assistant Professor M. Cvijic (Ljubljana, SI)
Abstract Slides Video
Presentation thumbnail
P-Selectin - predictor of venous thromboembolism in cancer patients?
Ms N. Diaconu (Chisinau, MD)
Abstract Slides Video
Presentation thumbnail
Endocarditis in patients with active malignant disease: a common condition with high rates of morbidity and mortality
Mr K. Rakhimov (Berlin, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology: around the world

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Echocardiographic variables may improve baseline risk prediction of cancer therapy related cardiac dysfunction
thumbnail
Congress Presentation
Are cancer survivors at greater risk of coronary artery disease?
thumbnail
Congress Presentation
Role of coronary calcium score and epicardial fat in stratifying baseline risk of cardiotoxicity in patients with gastrointestinal tumors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources